Alvotech (ALVO) to Announce Earnings on Wednesday

Key Points

• Alvotech is expected to report Q2 2026 results after market close on August 19. Analysts forecast a loss of $0.0526 per share and revenue of approximately $103.0 million; the earnings call is scheduled for August 20 at 8:00 a.m. ET.
• The company reported a $0.09-per-share loss and $105.9 million in revenue in its previous quarter, while maintaining negative profitability metrics, including a 14.36% net margin.
• Investor sentiment remains mixed: Alvotech has a consensus “Hold” rating and an average price target of $7.60, compared with a recent share price of $3.80. Several institutional investors increased their positions during the first and second quarters.

Alvotech (NASDAQ:ALVO - Get Free Report) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 19th. Analysts expect Alvotech to announce earnings of ($0.0526) per share and revenue of $103.0040 million for the quarter. Individuals may review the information on the company's upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:00 AM ET.

Alvotech (NASDAQ:ALVO - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.09) earnings per share (EPS) for the quarter. Alvotech had a negative net margin of 14.36% and a negative return on equity of 11.92%. The business had revenue of $105.90 million during the quarter. On average, analysts expect Alvotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alvotech Price Performance

NASDAQ ALVO opened at $3.80 on Wednesday. Alvotech has a fifty-two week low of $2.94 and a fifty-two week high of $9.25. The stock's 50-day moving average is $3.64 and its two-hundred day moving average is $3.80. The firm has a market cap of $1.15 billion, a P/E ratio of -15.20 and a beta of 0.18.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALVO. Wall Street Zen lowered Alvotech from a "hold" rating to a "sell" rating in a report on Saturday, May 23rd. Weiss Ratings lowered Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $7.60.

Institutional Investors Weigh In On Alvotech

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. lifted its position in shares of Alvotech by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company's stock worth $352,000 after purchasing an additional 10,573 shares during the last quarter. Geode Capital Management LLC increased its position in Alvotech by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company's stock worth $2,100,000 after buying an additional 1,574 shares during the period. Invesco Ltd. increased its position in Alvotech by 37.3% in the 2nd quarter. Invesco Ltd. now owns 32,398 shares of the company's stock worth $295,000 after buying an additional 8,794 shares during the period. Bank of America Corp DE lifted its holdings in shares of Alvotech by 218.0% during the second quarter. Bank of America Corp DE now owns 16,623 shares of the company's stock worth $152,000 after buying an additional 11,395 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Alvotech during the second quarter worth approximately $1,782,000.

Alvotech Company Profile

Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source